Every year, the Congressional Management Foundation (CMF) recognizes Members of Congress for their non-legislative achievements in operations, communications, and constituent services. U.S. Senator Marco Rubio (R-FL) was awarded the 2024 Democracy Award for...
News
Latest News
Rubio sobre la Toma de Posesión del Presidente Panameño
El senador estadounidense Marco Rubio (R-FL) emitió el siguiente comunicado sobre la toma de posesión del presidente panameño José Mulino: “A principios de este año, tras un proceso electoral pacífico y democrático, el pueblo de Panamá eligió al Presidente José...
Rubio Statement on Panamanian President’s Inauguration
U.S. Senator Marco Rubio (R-FL) issued the following statement regarding the inauguration of Panamanian President José Mulino: “Earlier this year, following a peaceful and democratic electoral process, the people of Panama elected President José Mulino as their new...
Rubio on State Department’s 2023 International Religious Freedom Report
Each year, the U.S. Department of State releases to Congress its International Religious Freedom Report. This report highlights the status of religious freedom in countries worldwide. U.S. Senator Marco Rubio (R-FL) issued the following statement regarding the release...
Next Week: Rubio Staff Hosts Mobile Office Hours
U.S. Senator Marco Rubio’s (R-FL) office will host in-person and virtual Mobile Office Hours next week to assist constituents with federal casework issues in their respective local communities. These office hours offer constituents who do not live close to one of...
ICYMI: Rubio: Biden Houthi Policy Hurts Americans
President Biden’s Misguided Policy toward the Houthis Hurts Americans U.S. Senator Marco Rubio (R-FL) June 27, 2024 National Review …Two weeks into his presidency, President Biden removed the Houthis from the foreign terrorist organization list…. [He] also ended...
ICYMI: Rubio Release Coronavirus Plan to Combat Supply Chain Risk, U.S. Dependence on China
My Coronavirus Plan: Combating America’s supply chain risk and dependence on China for pharmaceuticals
By U.S. Senator Marco Rubio (R-FL)
February 27, 2020
Medium
Across the world, news of the coronavirus outbreak is dominating headlines, and with good reason – the pandemic’s apparently high transmissibility rates and lethal danger it poses make it an exceptionally grave threat. The fact that China, ground zero for the virus and home to an overwhelming majority of ongoing cases, refuses to be transparent with its data adds to the seriousness of the situation.
As I wrote recently in an op-ed, the Chinese Communist Party is not a responsible global power, and the party’s blatant mishandling of the coronavirus has clearly revealed that.
Unfortunately, this was predictable.
Last year, I noted in Modern Healthcare that when it comes to the threat China poses to the U.S. healthcare industry, we cannot afford to be complacent.
And a report I released last February detailed critical vulnerabilities in America’s medical supply chain, warning, “the U.S. runs the risk of losing important components of its medical supply chain to China’s government-backed industry.”
At the time, those seemed like abstract concerns, but we now know they are real. Americans unable to buy medical masks and who see headlines about potential shortages of critical, irreplaceable drugs will be familiar.
The coronavirus outbreak makes clear how dependent our nation is on China for industrial capacity, especially in critical areas of our economy.
Health and Human Services Secretary Azar publicly acknowledged this on Tuesday when he confirmed to me that the coronavirus outbreak is “a wake-up call that perhaps we are overly dependent on a supply chain so heavily concentrated in one place in the world.”
That’s why I am planning to introduce legislation to curb America’s dependence on China that will:
- REQUIRE drugmakers to provide the Food and Drug Administration (FDA) with the volume of active pharmaceutical ingredients (API) derived from each manufacturing source,
- RESTORE Buy American Act preferences for pharmaceuticals, and
- COMBAT supply chain risk and U.S. dependence on China for APIs.